What did @antonpescador_md actually say?
The transcript here is heavily fragmented, likely due to auto-captioning errors on a multilingual video, so some interpretation is required. The core argument appears to be this: hypothyroidism can cause weight gain, and simply correcting thyroid hormone levels should restore normal metabolism. The creator seems to suggest that if a patient is already in a "normal thyroid state" or euthyroid, then weight-loss peptides or medications can be used as an "aid for weight loss and treatment" of obesity. They also reference seeing overweight or obese patients who struggle to lose weight due to undiagnosed or undertreated hypothyroidism.
Direct quote, as best as can be extracted: "by all means" use peptides once the patient is "already in the normal thyroid state." That sequencing is the central claim: fix thyroid first, then layer in adjunct therapies.
Does the science back this up?
Mostly, yes. The thyroid-first logic is sound clinical reasoning, and the endocrinology literature supports it. Thyroid hormones regulate basal metabolic rate through T3-mediated effects on mitochondrial activity and thermogenesis. When TSH is elevated and free T4 or T3 are low, you will see weight gain and metabolic slowing. Correcting this before chasing weight loss with adjunct treatments is not just reasonable, it is standard of care.
Pearce et al. (2013, New England Journal of Medicine) reviewed hypothyroid management and confirmed that adequate levothyroxine replacement does restore metabolic rate in most patients. However, a critical caveat: roughly 10-15% of treated hypothyroid patients still report persistent symptoms including difficulty losing weight even with normal TSH, a phenomenon documented by Saravanan et al. (2002, Journal of Clinical Endocrinology and Metabolism). This complicates the "fix thyroid, then everything normalizes" narrative more than the creator acknowledges.
What did they get wrong (or right)?
They got the sequencing right. Treating an underlying hormonal disorder before adding adjunct weight-loss therapies is good medicine. The creator deserves credit for not just throwing peptides or GLP-1 adjacent compounds at patients with unaddressed thyroid dysfunction.
Where the argument breaks down is the implication that correcting thyroid labs equals correcting weight-related metabolism fully. That is not always true. Hypothyroid patients on standard levothyroxine monotherapy often have lower T3 levels than the general population because they lack the natural T4-to-T3 conversion gradient. Idrees et al. (2021, Frontiers in Endocrinology) documented persistent metabolic deficits in treated hypothyroid patients. The creator does not address this nuance. Saying a patient is "euthyroid" on paper is not the same as saying their metabolism is functionally restored.
There is also no specific peptide named or dose discussed, which is actually appropriate here. The vagueness protects the creator from making specific therapeutic claims they cannot back up. That said, the phrase "aid for weight loss" applied to unnamed peptides is doing a lot of work with no citations behind it.
What should you actually know?
If you have been told you are struggling to lose weight because of hypothyroidism, the first step is genuinely getting your thyroid panel interpreted correctly, and that means more than just TSH. Free T3, free T4, and reverse T3 give a fuller picture. TSH alone can miss subclinical dysfunction. A 2019 systematic review by Eligar et al. in Thyroid found that combination T4 and T3 therapy improved quality of life in some patient subgroups who felt undertreated on levothyroxine alone.
On the peptide side: no compounded peptide has been approved by the FDA as a weight-loss treatment. Research on peptides like GHK-Cu or BPC-157 exists largely in animal models and small human trials. The idea that peptides are an appropriate "aid" for obesity once thyroid is corrected is not wrong in concept, but the evidence base is thin and the regulatory status of many of these compounds is actively shifting. The FDA has moved to restrict certain compounded peptides. Using them requires a licensed provider, a valid prescription, and a real conversation about what the evidence does and does not show.
Bottom line: the thyroid-first framework is clinically defensible. The jump to peptides as adjuncts is where you should press your provider for specifics, not take a TikTok at face value.